News | April 09, 2007

Masimo's Acoustic Respiratory Monitoring Technology

April 10, 2007 - Masimo, the inventor of Pulse CO-Oximetry and Read-Through Motion and Low Perfusion pulse oximetry, reported that three new independent studies, including one presented the recent International Anesthesiology Research Society (IARS) Clinical & Scientific Congress in Orlando, concluded that Masimo Acoustic Respiratory Monitoring technology (ARM) is "at least as accurate as capnometry" and "significantly more reliable" for monitoring respiration in spontaneously breathing patients.

Respiration is one of the five vital signs, but clinicians have long looked for a continuous and noninvasive method of monitoring respiration that is clinically accurate, easy to use and well tolerated by patients. Current methods of respiration monitoring, including impedance pneumography with ECG and end-tidal CO2 with capnometry, each have limitations that make them unreliable in certain clinical situations.

In the study released at the recent IARS, conducted by M. R. Macknet, MD and a team of researchers at Loma Linda University's Department of Anesthesiology, fifteen pediatric PACU patients were monitored with Masimo's ARM technology consisting of an adhesive bioacoustic sensor applied to the patient's neck and connected to a breathing frequency monitor prototype. In addition, a nasal cannula was placed, secured with tape, and connected to a capnometer. The study showed that "premature cannula dislodgement occurred in 14 patients" in less that 20 minutes, while "in no patient was the bioacoustic sensor dislodged before the end of the stay in the PACU."(1)

"This data shows the relative ease and high incidence of capnometer cannula dislodgement compared to the new bioacoustic sensor," the researchers commented. "In clinical settings where continuous and reliable monitoring of spontaneous respiration is important, the new bioacoustic sensor provides significantly greater patient connection time, which should lead to significantly more reliable monitoring of respiration rate."

In two studies released in January at the 2007 Society for Technology in Anesthesiology annual meeting, researchers monitored ten postoperative adult ICU and six pediatric PACU patients in separate studies with Masimo's ARM technology as well as a nasal cannula connected to a capnometer. They concluded that Masimo's new bioacoustic respiratory sensor "demonstrates accuracy for respiratory rate monitoring as good as capnometry" and that the device "offers multiple benefits over existing devices and has a potential to improve monitoring in a general care setting."(2),(3)

Joe E. Kiani, Founder & CEO of Masimo stated, "We are happy to see that these initial independent studies reinforce our belief that Masimo Acoustic Respiratory Monitoring has the potential to be a breakthrough continuous and noninvasive respiratory rate monitoring technology that is accurate, reliable and easy to use. Similar to Masimo SET Read-Through Motion and Low Perfusion pulse oximetry technology, we recognized that one of the other five primary vital signs had no available method of giving reliable results and decided to see if we could come up with a better solution. We are encouraged that the initial clinical research indicates that the non-obtrusive nature of the Masimo ARM technology application may help overcome the problems of conventional respiratory rate monitors without compromising measurement accuracy."

Masimo expects to combine its Masimo Rainbow SET Read-Through Motion and Low Perfusion pulse oximetry with Masimo ARM technology as part of a general floor monitoring solution designed to increase patient safety and heed the growing call to find ways to reduce unnecessary deaths on general care floors. The combination of these two technologies will give hospitals a continuous and noninvasive way to accurately monitor a patient's oxygenation and ventilation during patient-controlled analgesia, consistent with the new recommendations from the Anesthesia Patient Safety Foundation (APSF). In addition, the combination of Masimo Rainbow SET pulse oximetry and Masimo ARM should assist hospitals in being compliant with new American Society of Anesthesia (ASA) guidelines for management of patients at risk of obstructive sleep apnea (OSA) by providing an accurate and reliable combination of oxygen saturation and respiration rate monitoring.

The technology is currently undergoing additional clinical and engineering testing and is expected to be introduced at Alpha Sites in late 2007. For more information, visit www.masimo.com

Related Content

MD Anderson to Expand Proton Therapy Center

The MD Anderson Proton Therapy Center expansion is expected to be completed in 2023. Rendering courtesy of Stantec.

News | Proton Therapy | August 08, 2019
The University of Texas MD Anderson Cancer Center unveiled plans to expand its Proton Therapy Center during a...
AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...
The Beamscan 3-D water phantom with the Varian Halcyon radiotherapy system

The Beamscan 3-D water phantom with the Varian Halcyon radiotherapy system. Image courtesy of PTW.

News | Quality Assurance (QA) | July 08, 2019
At this year’s American Association of Physicists in Medicine (AAPM) show, July 14-18 in San Antonio, Texas, PTW will...
Study Identifies MRI-Guided Radiation Therapy as Growing Market Segment
News | Image Guided Radiation Therapy (IGRT) | June 06, 2019
Revenues from the magnetic resonance imaging (MRI)-guided radiation therapy systems market exceeded $220 million in...
Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carri Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
Accuray Launches Synchrony Motion Tracking and Correction Technology for Radixact System
Technology | Image Guided Radiation Therapy (IGRT) | April 24, 2019
Accuray announced the launch of its Synchrony motion tracking and correction technology to be used with the Radixact...
FDA Clears Advancements for Viewray MRIdian Radiation Therapy System
Technology | Image Guided Radiation Therapy (IGRT) | February 21, 2019
February 21, 2019 — ViewRay Inc. received 510(k) clearance from the U.S.
Elekta Unity MR-Linac Earns FDA Clearance
Technology | Image Guided Radiation Therapy (IGRT) | February 07, 2019
The Elekta Unity magnetic resonance radiation therapy (MR/RT) system recently received 510(k) premarket notification...
Elekta Introduces Strategy for Precision Radiation Medicine at ASTRO 2018

Elekta SmartClinic is one of the key features in the Mosaiq Plaza suite of data-focused integrative oncology software

News | Radiation Therapy | October 30, 2018
At the American Society for Radiation Oncology (ASTRO) Annual Meeting, Oct. 21-24 in San Antonio, Elekta introduced the...